Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;2(3):179-84.
doi: 10.4103/0976-500X.83283.

Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat

Papiya Bigoniya  1 , A Shukla, C S Singh, P Gotiya
Affiliations

Comparative anti-ulcerogenic study of pantoprazole formulation with and without sodium bicarbonate buffer on pyloric ligated rat

Papiya Bigoniya et al. J Pharmacol Pharmacother. 2011 Jul.

Abstract

Objective: To compare the anti-ulcer activity of buffered pantoprazole tablet against plain pantoprazole in pyloric ligated rats.

Materials and methods: In vivo pyloric ligated ulcerogenesis model was used to assess the effect of buffered pantoprazole on the volume of the gastric content, pH, total and free acidity, and ulcerogenic lesion. Pantoprazole level in gastric content and concurrently in stomach tissue was assessed by High Performance Liquid Chromatography (HPLC) analysis.

Results: Buffered tablet effectively increases the pH of the gastric content above 4 up to 6 h (P<0.001) protecting pantoprazole from acid degradation resulting in high concentration in the gastric content and stomach tissue.

Conclusions: This study substantiates better, faster and prolonged bioavailability of pantoprazole-buffered tablet compared to plain pantoprazole.

Keywords: Buffered tablet; pantoprazole; proton pump inhibitors; pyloric-ligation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Hoogerwerf WA, Pasricha PJ. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006. pp. 969–71.
    1. Brooks DC. Proton-Pump inhibitors (IV and oral) in the treatment of gastroesophageal reflux disease and related conditions. Medscape Today. 2004. [Last cited on 2009 Feb 02]. Available from: http://www.medscape.com/viewarticle/494197 .
    1. Ley LM, Stahlheber-Dilg B, Sander P, Huber R, Mascher H, Lucker PW. Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet. Methods Find Exp Clin Pharmacol. 2001;23:41–5. - PubMed
    1. Ferron GM, Ku S, Abell M, Unruh M, Getsy J, Mayer PR, et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health-Syst Pharm. 2003;60:1324–9. - PubMed
    1. Indian pharmacopoeia. Vol. 2. New Delhi: Govt. of India, Ministry of Health and Family Welfare; 1996. p. A 144.

LinkOut - more resources